Beta Bionics, Inc. BBNX 深 沪
等待开盘 10-08 09:30:00 美东时间
22.28
+0.330
+1.50%
华盛通- 最 高22.705
- 今 开21.65
- 成交量 18.18万股
- 最 低 21.57
- 昨 收 21.95
- 总市值 9.69亿
- 52周最高 26.66
- 市盈率 静 --
- 换手率 0.42%
- 52周最低 8.89
- 委 比 -93.44%
- 总股本 4347.01万
- 历史最高 26.66
- 量 比 0.38
- 振 幅 5.17%
- 历史最低 8.89
- 每 手 1
- 风险率 4.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅162.68%！Ocular Therapeutix获JMP证券升目标价至29美元，维持"跑赢大市"评级
今日重点评级关注：JMP证券：维持Ocular Therapeutix"跑赢大市"评级，目标价从20美元升至29美元；汇丰银行：上调Banco BBVA Argentina评级至"买入"，目标价从21美元下调至17美元
10-02 15:08
Forecasting The Future: 4 Analyst Projections For Beta Bionics
During the last three months, 4 analysts shared their evaluations of Beta Bioni...
10-02 04:00
Doximity, LivaNova downgraded as Goldman Sachs reviews MedTech and Health IT coverage
Doximity (NYSE:DOCS), a digital platform for medical professionals, and LivaNova (NASDAQ:LIVN), a medical equipment maker, traded lower on Wednesday after Goldman Sachs downgraded the duo as part of a...
10-02 01:57
Goldman Sachs Upgrades Beta Bionics to Buy, Raises Price Target to $26
Goldman Sachs analyst David Roman upgrades Beta Bionics (NASDAQ:BBNX) from Neutral to Buy and raises the price target from $18 to $26.
10-02 01:32
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $28
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $21 to $28.
09-22 21:59
Beta Bionics Announces Participation at Upcoming Investor Conferences
Beta Bionics Inc. will present at three upcoming investor conferences: the Wells Fargo 20th Annual Healthcare Conference on September 4, 2025, the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, and the Baird 2025 Global Healthcare Conference on September 10, 2025. The presentations at the first two conferences will be webcast live and archived on the company’s website. Beta Bionics, a medical device company, focuses...
08-21 12:00
Baird Maintains Neutral on Beta Bionics, Raises Price Target to $17
Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and raises the price target from $15 to $17.
07-30 22:20
Beta Bionics Raises FY2025 Sales Guidance from $82.00M-$87.00M to $88.00M-$93.00M vs $84.73M Est
Beta Bionics (NASDAQ:BBNX) raises FY2025 sales outlook from $82.00 million-$87.00 million to $88.00 million-$93.00 million vs $84.73 million estimate.
07-30 04:04
Beta Bionics Q2 EPS $(0.39) Beats $(0.47) Estimate, Sales $23.24M Beat $19.68M Estimate
Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.47) by 16.67 percent. The company reported quarterly sales of $23.24 million which beat the
07-30 04:03
